Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
about
Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patientsRoutine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing.Digital detection of T790M-yes or no to an ultrasensitive assay.Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal FluidTumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing.Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.Liquid biopsies in lung cancer-time to implement research technologies in routine care?Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.Addressing intra-tumoral heterogeneity and therapy resistance.Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.Liquid Biopsy in Non-Small Cell Lung Cancer.Liquid biopsies come of age: towards implementation of circulating tumour DNA.Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.Profiling Non-Small Cell Lung Cancer: From Tumor to Blood.Collection of cell-free DNA for genomic analysis of solid tumors in a clinical laboratory setting.Adenocarcinoma of the lung with EGFR gene mutation and subsequent resistance mechanisms exploration: case report.Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysisCons: Can liquid biopsy replace tissue biopsy?-the US experience.Rebuttal from Dr. Mino-Kenudson.The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer.NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients.Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer.Blood-based tumor biomarkers in lung cancer for detection and treatment.Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology.New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer.Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System?Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.Molecular biology tools for precision medicine in managing lung cancer.Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer.Tumour heterogeneity and resistance to cancer therapies.Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer.Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients.A Comparative Study for Detection of EGFR Mutations in Plasma Cell-Free DNA in Korean Clinical Diagnostic Laboratories.Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.
P2860
Q26738390-64EA3DDB-429D-4B28-99F2-FF4D2C97DEABQ28067439-C0350774-CCD9-4AC6-A803-29185E849485Q33599057-3AD84A24-4BD4-4FA4-AF6B-F4C97B004CCAQ37060732-C0C12AD2-F7EA-419E-BAA3-DEBAE6727DFEQ37168845-4CBDF818-789A-4E75-A146-89F1A30D67DDQ37462554-CCD4FE39-A43B-4715-89A3-B24ACE7EF98DQ37662209-CF4F2B99-C6F4-466E-AF9F-F43DD71DC8F4Q37690677-455C86E1-50D9-42AE-BF64-F3994E78DB07Q38649535-F619F9F0-C383-4881-9461-F5E55D750F36Q38717500-9EE296D8-4B7E-452A-AF67-7922FF874E9CQ38823179-FF9E907A-E363-4812-948B-043EF36BD909Q38824891-CAE7897F-E3D0-44B3-8E1A-CC9CF3ACDF22Q39076207-633C55EC-3293-4EA9-B56D-57878A0D35CBQ39149201-7892AC40-3452-4278-A665-D875447C0812Q39197920-0B479D59-91A5-4E34-B323-89BF502E4076Q40364937-38CED2DD-1661-4FC2-B4DD-F5B91FD605E9Q40393934-1329BFF0-F7D6-411D-81C2-F4AB0514E16EQ40868929-DEA4ED57-57BA-481B-A27C-BA22B89E06E7Q42057245-BDEFA4F1-4F3E-4E0D-8B49-DCE08E63E22DQ42360043-C451894A-3F7F-4D19-89F9-3BE333C9C1FCQ42371507-F44D638E-011E-416E-9BF1-7004B87BB8A6Q42398713-6ACDE2F7-4BA3-4522-B9D5-7D70266D2FE5Q42398715-0E3AC4B6-9623-4189-9F73-3DC425B64EB5Q42643276-22E144FF-2F72-4D76-87D3-C1AEB48AEA14Q42695934-B85FD559-4534-4566-9F9A-C9B4CD6CDA43Q46030309-5F34F96E-D6E4-4E06-97EE-09EF6D00D022Q46137433-68CF199F-4A6B-4154-9057-23C2A8F0375FQ47126156-09F85670-DC36-469A-8274-D5D1DFB45739Q47153925-9AD2D9D9-5C4E-4540-B769-46A749BA161AQ47159366-D1342C70-06BF-4315-BFAC-2FCA98D999B7Q47162466-5344D220-558E-4192-BC0F-33179A33C8FAQ47563363-0177BDDF-B5B7-46EC-8FB1-29CE9BDE59B9Q48507434-204C7FE9-090D-4825-82F4-FC76310C37BAQ49658290-FA6283D1-D978-4161-B421-97089F5A9657Q49740946-DDD422ED-F541-49C0-B634-44448A1BE076Q50112440-9BD785CC-9178-46E8-B2C9-28129B4744F7Q52723096-06DB444C-B75C-4E45-B853-ACDE63B94920Q53688649-5D0D1918-B87C-4976-9EE8-412A52E769BAQ55129047-319F15F5-D200-4D96-856B-46F57CF7A768Q55334265-02A9280B-293A-44C6-850B-45585C0973AE
P2860
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Bias-Corrected Targeted Next-G ...... Advanced Lung Cancer Patients.
@ast
Bias-Corrected Targeted Next-G ...... Advanced Lung Cancer Patients.
@en
type
label
Bias-Corrected Targeted Next-G ...... Advanced Lung Cancer Patients.
@ast
Bias-Corrected Targeted Next-G ...... Advanced Lung Cancer Patients.
@en
prefLabel
Bias-Corrected Targeted Next-G ...... Advanced Lung Cancer Patients.
@ast
Bias-Corrected Targeted Next-G ...... Advanced Lung Cancer Patients.
@en
P2093
P2860
P50
P1476
Bias-Corrected Targeted Next-G ...... Advanced Lung Cancer Patients.
@en
P2093
Allison O'Connell
Chris K Raymond
Cloud P Paweletz
Geoffrey R Oxnard
Jessie M English
Paul Kirschmeier
Ryan S Alden
Stacy L Mach
Yanan Kuang
P2860
P304
P356
10.1158/1078-0432.CCR-15-1627-T
P407
P577
2015-10-12T00:00:00Z